| Literature DB >> 26273422 |
Se-Ran Yang1, Jeong-Ran Park2, Kyung-Sun Kang3.
Abstract
MSCs have become an emerging cell source with their immune modulation, high proliferation rate, and differentiation potential; indeed, they have been challenged in clinical trials. Recently, it has shown that ROS play a dual role as both deleterious and beneficial species depending on their concentration in MSCs. Various environmental stresses-induced excessive production of ROS triggers cellular senescence and abnormal differentiation on MSCs. Moreover, MSCs have been suggested to participate in the treatment of ALI/ARDS and COPD as a major cause of high morbidity and mortality. Therapeutic mechanisms of MSCs in the treatment of ARDS/COPD were focused on cell engraftment and paracrine action. However, ROS-mediated therapeutic mechanisms of MSCs still remain largely unknown. Here, we review the key factors associated with cell cycle and chromatin remodeling to accelerate or delay the MSC aging process. In addition, the enhanced ROS production and its associated pathophysiological pathways will be discussed along with the MSC senescence process. Furthermore, the present review highlights how the excessive amount of ROS-mediated oxidative stress might interfere with homeostasis of lungs and residual lung cells in the pathogenesis of ALI/ARDS and COPD.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26273422 PMCID: PMC4529978 DOI: 10.1155/2015/486263
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1ROS-dependent cellular senescence pathways in MSCs. Similar to other adult somatic cells, MSCs enter replicative senescence after a certain number of cell divisions. ROS are responsible for cellular senescence and cause a direct DNA damage. DNA damage triggers a specific DNA damage response (DDR). DDR activation leads to cell cycle arrest via activation of p53/p21 and/or p16/pRB pathway. In addition, MAPK pathway is required for the acquisition of senescence. P38 plays an important causative role in cellular senescence induced by oxidative stress. Furthermore, ROS regulate major epigenetic processes and can induce DNA methylation and histone acetylation. Understanding the mechanism of senescence of MSCs should provide more effective strategies in transplantation of MSCs into the recipients with age-related diseases inherently associated with increased levels of oxidative stress.
Figure 2The role of ROS in COPD and ARDS. In COPD, aging and cigarette smoke increase the generation of ROS, leading to the upregulation of inflammatory signaling in alveolar type II cells. In ARDS, endotoxin and shock induce the infiltration of neutrophils into interstitial, and chromatin changes are involved. In the pathogenesis of COPD and ARDS, ROS-induced neutrophils are recruited in alveoli, and production of ROS is rapidly accumulated, derived from infiltrated neutrophils, and activated macrophages.
Potential mechanisms of action of mesenchymal stem cell in animal models of lung diseases.
| Source | Injury model | Cell delivery route | Finding and mechanism of action | Reference |
|---|---|---|---|---|
| Acute respiratory distress syndrome (ARDS)/acute lung injury/pneumonia | ||||
|
| ||||
| Bone marrow-derived MSCs | Murine model in LPS-induced ALI (i.t) | i.t | Both functional and survival advantages with histological improvement in the severity of lung injury without engrafting through to stem cell chemoattractants | [ |
| Rodent model in endotoxin-induced ALI (i.v) | i.v | The beneficial effect of MSCs overexpressing HO-1 might be achieved through the engraftment of differentiated MSCs in lung through secretion of paracrine factors | [ | |
| Rodent model in paraquat poisoning-induced ALI (i.p) | i.v | Inhibit the release of inflammatory mediator, lung edema, and lipid peroxidation | [ | |
| Rodent model in LPS-induced ALI (i.t) | Intrapleural delivery | Attenuate the severity of ALI by mediating paracrine/endocrine repair mechanism than by the cell engraftment mechanism | [ | |
| Murine model in LPS-induced ALI (i.t) | i.t | The therapeutic properties of MSCs can be recapitulated by the MV that MSCs actively secrete in culture through KGF | [ | |
| Murine model in LPS- or CLP-induced ALI (i.p) | i.t | MSCs therapy at day 1 reduces lung inflammation and remodeling for each type of initial insult triggering extrapulmonary ARDS; MSCs increase MMP8 and decreaseTIMP1; MSCs shift macrophage | [ | |
|
| ||||
| Adipose tissue-derived MSCs | Rodent model in IR-induced ALI | i.v | Autologous ASCs suppress inflammatory response and oxidative stress (increased NAD(P)H, HO-1) as well as enhancement of angiogenesis (VCAM1, ICAM-1) | [ |
| Rodent model in LPS-induced ALI (i.v) | i.v | Decrease inflammatory cytokine levels in serum and lung as well as reduce alveolar inflammatory cell infiltration in the lung and protected multiorgan injury | [ | |
| Murine model in LPS-induced ALI (i.t) | O.A | Attenuates neutrophil influx and inflammation due to the increased production of IL-10 | [ | |
|
| ||||
| Umbilical cord-derived MSCs | Murine model in LPS-induced ALI (i.t) | i.t | Several clinical advantages that provide expansion of CD4+CD25+Foxp3+Treg cells, balancing anti- and proinflammatory factors as well as bacterial clearance | [ |
| Rodent model in LPS-induced ALI (i.t) | i.v | Reduces TNF- | [ | |
|
| ||||
| MSCs from other tissues | Murine model in LPS-induced ALI (i.t) | i.v | Systemic orbital fat-derived stem/stromal cells are effective in modulating inflammation | [ |
|
| ||||
| Chronic obstructive pulmonary disease (COPD)/emphysema | ||||
|
| ||||
| Bone marrow-derived MSCs | Rodent model in CS-induced emphysema (6 m) | i.t or i.v | Increased VEGF-A and inhibited the apoptosis (Bax, Bcl-2) of lung alveolar cells; TNF- | [ |
| Rodent model in CS-induced emphysema (11 w) | i.t | A therapeutic potential in parenchymal repair by increased levels of growth factors and decreased cell apoptosis through VEGF, VEGF receptor, and TGF | [ | |
|
| ||||
| Adipose tissue-derived MSCs | Murine model in PPE-induced emphysema (i.t) | i.t | ASCs ameliorate damage of alveolar structure through the release of soluble humoral factor (HGF, EGF, and SLP1) | [ |
(i.t): intratracheal; (i.v): in vein; (i.p): intraperitoneal.